Anne Bass, MD: Emerging Treatments in Inflammatory Disease

Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, talks about some emerging treatments in inflammatory disease.
July 03, 2018


Transcript

Are there some emerging directions in treating inflammatory disease that you’re particularly excited about?


I think the area that we most need to work on is trying to figure out which patients do the best on which therapies. Some patients do very well the first thing you use, but we’ve all had experience with patients who need to cycle through a variety of medications before we find the 1 or the combination medicines that works just right for them. It would be wonderful if we had a test from the beginning that could tell us that we need to target 1 pathway and 1 patient, and a different pathway and a different patient. We’re not there yet, but that’s certainly a direction that we’re moving in as we begin to understand these diseases on a deeper level pathogenetically.
 

x-button
Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.